

Table 1. Representative comparison of vaccine effectiveness against SARS-CoV-2 infection across different studies during period of predominant Omicron infection

Vaccine dosage	Comparator group	Population	Number of weeks since last dose	Reported vaccine effectiveness (%)	Reference
BNT162b2 (Primary)	COVID-negative	Adult (27 Nov 2021 to 12 Jan 2022)	2–4	65.5	<sup>68</sup>
			>25	8.8	
BNT162b2 (First booster, primary: ChAdOx1 nCoV-19)			2–4	62.4	
			>10	39.6	
mRNA-1273 (First booster, primary: ChAdOx1 nCoV-19)			2–4	70.1	
			5–9	60.9	
mRNA-1273 (First booster, primary: ChAdOx1 nCoV-19)			2–4	73.9	
			5–9	64.4	
BNT162b2 (Second booster)	BNT162b2 (First booster)	Long-term care facility resident (10 January 2022 to 31 March 2022)	>1	34	<sup>63</sup>

Superscript reference numbers: Refer to REFERENCES